Published online before print January 5, 2006, doi: 10.1161/01.RES.0000202805.73038.48
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Molecular Medicine |
The Transforming Growth Factor-ß Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury
From the Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany (T.K., M.E., M.N., C.W., J.T., J.H., D.K., H.D., K.C.W.); Department of Neuroanatomy, University of Heidelberg, Germany (J.S.); Division of Molecular Cardiovascular Biology, University of Cincinnati, Ohio (J.X., J.D.M.); and Department of Pathology, University Medical Center, Amsterdam, The Netherlands (H.W.N.).
Correspondence to Priv-Doz Dr Kai C. Wollert, Abt. Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg Str.1, 30625 Hannover, Germany. E-mail wollert.kai{at}mh-hannover.de
Data from the Women’s Health Study show that serum levels of growth-differentiation factor-15 (GDF-15), a distant member of the transforming growth factor-ß superfamily, are an independent risk indicator for adverse cardiovascular events. However, the cellular sources, upstream regulators, and functional effects of GDF-15 in the cardiovascular system have not been elucidated. We have identified GDF-15 by cDNA expression array analysis as a gene that is strongly upregulated by nitrosative stress in cultured cardiomyocytes isolated from 1- to 3-day-old rats. GDF-15 mRNA and pro-peptide expression levels were also induced in cardiomyocytes subjected to simulated ischemia/reperfusion (I/R) via NO–peroxynitrite-dependent signaling pathways. GDF-15 was actively secreted into the culture supernatant, suggesting that it might exert autocrine/paracrine effects during I/R. To explore the in vivo relevance of these findings, mice were subjected to transient or permanent coronary artery ligation. Myocardial GDF-15 mRNA and pro-peptide abundance rapidly increased in the area-at-risk after ischemic injury. Similarly, patients with an acute myocardial infarction had enhanced myocardial GDF-15 pro-peptide expression levels. As shown by immunohistochemistry, cardiomyocytes in the ischemic area contributed significantly to the induction of GDF-15 in the infarcted human heart. To delineate the function of GDF-15 during I/R, Gdf-15 gene-targeted mice were subjected to transient coronary artery ligation for 1 hour followed by reperfusion for 24 hours. Gdf-15–deficient mice developed greater infarct sizes and displayed more cardiomyocyte apoptosis in the infarct border zone after I/R compared with wild-type littermates, indicating that endogenous GDF-15 limits myocardial tissue damage in vivo. Moreover, treatment with recombinant GDF-15 protected cultured cardiomyocytes from apoptosis during simulated I/R as shown by histone ELISA, TUNEL/Hoechst staining, and annexin V/propidium iodide fluorescence-activated cell sorting (FACS) analysis. Mechanistically, the prosurvival effects of GDF-15 in cultured cardiomyocytes were abolished by phosphoinositide 3-OH kinase inhibitors and adenoviral expression of dominant-negative Akt1 (K179M mutation). In conclusion, our study identifies induction of GDF-15 in the heart as a novel defense mechanism that protects from I/R injury.
Key Words: growth-differentiation factor-15 • ischemia/reperfusion • apoptosis • PI3K • Akt
This article has been cited by other articles:
 |
|
 |
|
  P. W.X. Foley, B. Stegemann, K. Ng, S. Ramachandran, A. Proudler, M. P. Frenneaux, L. L. Ng, and F. Leyva Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy Eur. Heart J., November 2, 2009; 30(22): 2749 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Seki, S. Sanada, A. Y. Kudinova, M. L. Steinhauser, V. Handa, J. Gannon;, and R. T. Lee Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling Circ Heart Fail, November 1, 2009; 2(6): 684 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oshima, N. Ouchi, M. Shimano, D. R. Pimentel, K. N. Papanicolaou, K. D. Panse, K. Tsuchida, E. Lara-Pezzi, S.-J. Lee, and K. Walsh Activin A and Follistatin-Like 3 Determine the Susceptibility of Heart to Ischemic Injury Circulation, October 20, 2009; 120(16): 1606 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lind, L. Wallentin, T. Kempf, H. Tapken, A. Quint, B. Lindahl, S. Olofsson, P. Venge, A. Larsson, J. Hulthe, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study Eur. Heart J., October 1, 2009; 30(19): 2346 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sugulle, R. Dechend, F. Herse, M. S. Weedon-Fekjaer, G. M. Johnsen, K. B. Brosnihan, L. Anton, F. C. Luft, K. C. Wollert, T. Kempf, et al. Circulating and Placental Growth-Differentiation Factor 15 in Preeclampsia and in Pregnancy Complicated by Diabetes Mellitus Hypertension, July 1, 2009; 54(1): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rohatgi and J. A. de Lemos The Report Card on Growth Differentiation Factor 15: Consistent Marks But Not Yet Ready for Promotion Circ Cardiovasc Genet, June 1, 2009; 2(3): 209 - 211. [Full Text] [PDF]
|
|
|
|
|
|
T. Kempf, J.-M. Sinning, A. Quint, C. Bickel, C. Sinning, P. S. Wild, R. Schnabel, E. Lubos, H. J. Rupprecht, T. Munzel, et al. Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease: Results From the AtheroGene Study Circ Cardiovasc Genet, June 1, 2009; 2(3): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Q. Khan, K. Ng, O. Dhillon, D. Kelly, P. Quinn, I. B. Squire, J. E. Davies, and L. L. Ng Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction Eur. Heart J., May 1, 2009; 30(9): 1057 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Korf-Klingebiel, T. Kempf, T. Sauer, E. Brinkmann, P. Fischer, G. P. Meyer, A. Ganser, H. Drexler, and K. C. Wollert Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction Eur. Heart J., December 1, 2008; 29(23): 2851 - 2858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Bjornstad, N. O. Neverdal, O. A. Vengen, C. W. Knudsen, T. Husebye, J. Pepper, M. Lie, G. Christensen, and T. Tonnessen Alterations in circulating activin A, GDF-15, TGF-{beta}3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis Eur J Heart Fail, December 1, 2008; 10(12): 1201 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Eggers, T. Kempf, T. Allhoff, B. Lindahl, L. Wallentin, and K. C. Wollert Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain Eur. Heart J., October 1, 2008; 29(19): 2327 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nickel, T. Kempf, H. Tapken, J. Tongers, F. Laenger, U. Lehmann, H. Golpon, K. Olsson, M. R. Wilkins, J. S. R. Gibbs, et al. Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 534 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oshima, N. Ouchi, K. Sato, Y. Izumiya, D. R. Pimentel, and K. Walsh Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart Circulation, June 17, 2008; 117(24): 3099 - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lankeit, T. Kempf, C. Dellas, M. Cuny, H. Tapken, T. Peter, M. Olschewski, S. Konstantinides, and K. C. Wollert Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1018 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells Carcinogenesis, April 1, 2008; 29(4): 704 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Frank, C. Kuhn, B. Brors, C. Hanselmann, M. Ludde, H. A. Katus, and N. Frey Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program Hypertension, February 1, 2008; 51(2): 309 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kempf, E. Bjorklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter, J. Tongers, K. C. Wollert, and L. Wallentin Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction Eur. Heart J., December 1, 2007; 28(23): 2858 - 2865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Wollert, T. Kempf, B. Lagerqvist, B. Lindahl, S. Olofsson, T. Allhoff, T. Peter, A. Siegbahn, P. Venge, H. Drexler, et al. Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome Circulation, October 2, 2007; 116(14): 1540 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kempf, S. von Haehling, T. Peter, T. Allhoff, M. Cicoira, W. Doehner, P. Ponikowski, G. S. Filippatos, P. Rozentryt, H. Drexler, et al. Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1054 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maisel Biomarkers in Heart Failure: Does Prognostic Utility Translate to Clinical Futility? J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1061 - 1063. [Full Text] [PDF]
|
|
|
|
|
|
K. C. Wollert, T. Kempf, T. Peter, S. Olofsson, S. James, N. Johnston, B. Lindahl, R. Horn-Wichmann, G. Brabant, M. L. Simoons, et al. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non-ST-Elevation Acute Coronary Syndrome Circulation, February 27, 2007; 115(8): 962 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kempf, R. Horn-Wichmann, G. Brabant, T. Peter, T. Allhoff, G. Klein, H. Drexler, N. Johnston, L. Wallentin, and K. C. Wollert Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay Clin. Chem., February 1, 2007; 53(2): 284 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fiedler, R. Feil, F. Hofmann, C. Willenbockel, H. Drexler, A. Smolenski, S. M. Lohmann, and K. C. Wollert cGMP-dependent Protein Kinase Type I Inhibits TAB1-p38 Mitogen-activated Protein Kinase Apoptosis Signaling in Cardiac Myocytes J. Biol. Chem., October 27, 2006; 281(43): 32831 - 32840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Morissette, S. A. Cook, S. Foo, G. McKoy, N. Ashida, M. Novikov, M. Scherrer-Crosbie, L. Li, T. Matsui, G. Brooks, et al. Myostatin Regulates Cardiomyocyte Growth Through Modulation of Akt Signaling Circ. Res., July 7, 2006; 99(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ago and J. Sadoshima GDF15, a Cardioprotective TGF-{beta} Superfamily Protein Circ. Res., February 17, 2006; 98(3): 294 - 297. [Full Text] [PDF]
|
|